Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open study of quadrivalent VN-100 in healthy children
jRCT2080222939Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2015
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of VN-100 in influenza, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Hemagglutination inhibition (HI) antibody titer immunogenicity. Started Aug 2015; status: completed.
02
Drugs
VN-100
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2080222939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222939.